Natalya Belotserkovskaya, MD
Neurology · Birmingham, ALNPI 1164833323
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Biogen at 39.4% of the total. Reporting peaked in 2022 at $17,826 and has fallen 62.0% since, to $6,774 in 2025.
Across 854 payments — averaging $48.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$16K
- Amgen$4K
- Pfizer$3K
- Genentech USA, Inc.$2K
- AbbVie$2K
- Novartis$1K
- plus $12K from 50 others
What the payments were for
- Consulting fees$8,32920%
- Speaking & faculty fees$14,63235%
- Food & beverage$18,55344%
- Education$2411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,755 in reported general payments places this provider in the 85th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 33 | $279,986 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $221,495 |
| MayzentSiponimod | 13 | $144,830 |
| UbrelvyUbrogepant | 54 | $71,177 |
| CopaxoneGlatiramer Acetate | 11 | $63,122 |
| Emgality PenGalcanezumab-Gnlm | 59 | $41,170 |
| GlatopaGlatiramer Acetate | 22 | $37,718 |
| Nurtec OdtRimegepant Sulfate | 20 | $32,438 |
| EliquisApixaban | 45 | $27,681 |
| QuliptaAtogepant | 21 | $22,197 |
| BriviactBrivaracetam | 12 | $19,659 |
| Glatiramer Acetate | 14 | $19,416 |
| Lacosamide | 89 | $17,283 |
| Rivastigmine | 67 | $13,709 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $12,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $308 | $221,49526 claims |
| NovartisMayzent | $1,425 | $144,83013 claims |
| AbbVieUbrelvy, Qulipta | $2,312 | $93,37475 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $289 | $63,12211 claims |
| PfizerNurtec Odt, Eliquis | $2,610 | $60,11865 claims |
| UCB, Inc.Briviact | $1,150 | $19,65912 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $97 | $2,37335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.